Invitation to Year End 2011 and Q4 Results Conference Call of MorphoSys AG on March 01, 2012

Thursday, 23. February 2012 15:00
MorphoSys AG /
Invitation to Year End 2011 and Q4 Results Conference Call of MorphoSys AG on
March 01, 2012
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual
Financial Results 2011 on March 01, 2012 at 7:00 a.m. CET.

The Management team of MorphoSys AG will host a conference call and webcast to
present MorphoSys's Annual Financial Results 2011 and provide an outlook for

DATE:                              Thursday, March 01, 2012
TIME:                               02:00 p.m. CET (01:00 p.m. GMT, 08:00 a.m.

DIAL IN No:                    +49 (0) 89 2444 329 75
UK RESIDENTS:          +44 (0) 20 3003 2666
US RESIDENTS:          +1 212 999 6659

Participants of the call are:

Dr. Simon Moroney, Chief Executive Officer
Jens Holstein, Chief Financial Officer
Dr. Marlies Sproll, Chief Scientific Officer
Dr. Arndt Schottelius, Chief Development Officer

We request that you please dial in up to 10 minutes before the call to ensure a
prompt start and a secure line.

The presentation slides and webcast link will be available at the Company's
website at

A slide-synchronized audio replay of the conference will also be available at
the corporate website following the live event.

In case of any further questions please contact:

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & Investor Relations
Tel: +49 89 899 27-122
Fax: + 49 89 899 27-5122

Mario Brkulj
Senior Manager Corporate Communications & Investor Relations
Tel: +49 (0) 89 / 899 27-454
Fax: +49 (0) 89 / 899 27-5454

Jessica Kulpi
Specialist Corporate Communications & Investor Relations
Tel: +49 (0) 89 / 899 27-332
Fax: +49 (0) 89 / 899 27-5332

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia®
are registered trademarks of MorphoSys AG. 100 billion high potentials(TM) is a
trademark of MorphoSys AG.

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Conference Alert:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

Related Links: MorphoSys AG
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.